OMICS Group is among best open access publishers with expert reviewers and renowned scientists in its Editorial Board. Both editors and reviewers actively participate in the peer-review process and help in completing the review process within 21 days. Apart from this OMICS Group organizes more than 80 International Scientific conferences.
Del Chiaro et al. presented preliminary results of an MR-based screening program for pancreatic cancer in individuals at risk. These patients were identified based on personal and family history. Forty patients were enrolled between 2010 and 2013. They were screened for genetic mutations associated with pancreatic cancer development. A p16 mutation was noted in 4 (10%) patients, BRCA2 mutation in 3 (8%) and BRCA1 mutation in 1 patient (3%). The mean length of follow-up was 12.9 months and patients underwent MR at time of enrollment and intervals were determined based on findings. Sixteen (40%) of patients had positive findings on MR surveillance. Fourteen (35%) patients were found to have an IPMN and 2 (5%) were found to have pancreatic cancer. Five (13%) of patients underwent surgical intervention. Interestingly, the number of family members with pancreatic cancer did not correlate with the likelihood of development of abnormal findings. This study, though limited by current follow-up of approximately one year, suggests that, in a well-defined population, an MR-based screening program could be effective in pancreatic cancer.
Citation: Del Chiaro M, Verbeke C, et al. Preliminary Results of a Swedish, MR Based, Screening Program for Individuals at Risk for Pancreas Cancer. Paper presented at the 48th Annual Meeting of the Pancreas Club; May 2014; Chicago, Illinois, USA.
Last date updated on October, 2020